Get the Stockscreener App
142.53
0.68%
-0.97
After Hours:
141.08
-1.45
-1.02%
Insmed Inc stock is traded at $142.53, with a volume of 2.01M.
It is down -0.68% in the last 24 hours and up +28.13% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$143.50
Open:
$142.86
24h Volume:
2.01M
Relative Volume:
0.53
Market Cap:
$30.13B
Revenue:
$398.11M
Net Income/Loss:
$-1.03B
P/E Ratio:
-25.05
EPS:
-5.69
Net Cash Flow:
$-868.57M
1W Performance:
+5.60%
1M Performance:
+28.13%
6M Performance:
+84.60%
1Y Performance:
+89.41%
1-Day Range:
$141.25
$145.00
1-Week Range:
$134.39
$146.84
52-Week Range:
$60.40
$146.84
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
142.53 | 30.71B | 398.11M | -1.03B | -868.57M | -5.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed CMO Flammer sells $26.9m in stock after option exercise - Investing.com
Insmed CLO Smith sells $3.49m in shares - Investing.com
Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri - Yahoo Finance
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease - MSN
Should you wait for a breakout in Insmed IncorporatedJuly 2025 Trade Ideas & Proven Capital Preservation Methods - Newser
Will Insmed Incorporated stock hit new highs in YEARTreasury Yields & Detailed Earnings Play Alerts - khodrobank.com
Insmed Shares Slide 1.24% Amid 48.65% Volume Drop to 286th Rank as Wells Fargo Raises Target to $171 - AInvest
Trend Review: Will Insmed Incorporated benefit from rate cutsRecession Risk & Smart Money Movement Alerts - khodrobank.com
Analyzing drawdowns of Insmed Incorporated with statistical tools2025 Market Sentiment & Free Real-Time Market Sentiment Alerts - Newser
Key resistance and support levels for Insmed IncorporatedQuarterly Growth Report & Capital Efficient Trading Techniques - Newser
Is Insmed Incorporated forming a reversal patternTrade Signal Summary & Growth Oriented Trading Recommendations - Newser
Live market analysis of Insmed IncorporatedShare Buyback & Step-by-Step Trade Execution Guides - Newser
Analyzing net buyer seller activity in Insmed IncorporatedWeekly Trend Summary & Real-Time Stock Movement Alerts - Newser
Signal strength of Insmed Incorporated stock in tech scannersGlobal Markets & Smart Money Movement Tracker - Newser
Sentiment analysis tools applied to Insmed IncorporatedWeekly Stock Analysis & Daily Entry Point Trade Alerts - Newser
Chart based exit strategy for Insmed IncorporatedEarnings Beat & Risk Controlled Stock Alerts - Newser
Is Insmed Incorporated still worth holding after the dip2025 Market Sentiment & Real-Time Stock Price Movement Reports - Newser
Insmed (INSM) Soars 6.76% After FDA Approves Brinsupri for Non-CF Bronchiectasis - AInvest
Will Insmed Incorporated outperform small cap indexesWeekly Trade Review & AI Forecast for Swing Trade Picks - khodrobank.com
Insmed (INSM) Surges 6.76% on Bullish Technical Signals Faces Key Resistance at $140 - AInvest
Is Insmed Incorporated stock forming a cup and handleMarket Sentiment Summary & Entry Point Confirmation Alerts - khodrobank.com
Why United Just Catapulted 39%, Pulling Two Rivals With It - Investor's Business Daily
Brinsupri Boost: Is Insmed Stock Undervalued? - StocksToTrade
What high frequency data says about Insmed Incorporated2025 AllTime Highs & Free Daily Entry Point Trade Alerts - Newser
Insmed Stock Soars: Buy or Hold Timeout? - timothysykes.com
Insmed Stock Jumps: What’s Driving Change? - StocksToTrade
What analysts say about Insmed Incorporated stockEarnings Risk Report & Growth Focused Stock Pick Reports - khodrobank.com
Buy Rating for Insmed: Promising Market Potential and Strategic Advancements in TPIP Development - TipRanks
Will earnings trigger a reversal in Insmed IncorporatedWeekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser
Insmed Surges 5.9% on Intraday Rally: What’s Fueling the Momentum? - AInvest
Custom watchlist performance reports with Insmed Incorporated2025 Sector Review & Safe Investment Capital Preservation Plans - Newser
S&P 500 Futures Decline in Premarket Trading; Insmed, Millrose Properties Lead - Barron's
Combining price and volume data for Insmed IncorporatedWeekly Loss Report & High Conviction Trade Alerts - Newser
Is Insmed Incorporated forming a double bottomJuly 2025 Technicals & Long-Term Growth Stock Strategies - khodrobank.com
What Fibonacci levels say about Insmed Incorporated reboundJuly 2025 Setups & Technical Pattern Based Buy Signals - Newser
Is it time to cut losses on Insmed IncorporatedWeekly Investment Summary & Accurate Buy Signal Alerts - Newser
Published on: 2025-09-01 13:30:18 - beatles.ru
Is this a good reentry point in Insmed IncorporatedTrade Ideas & Expert Curated Trade Ideas - Newser
Analyzing Insmed Incorporated with risk reward ratio chartsJuly 2025 Sector Moves & High Win Rate Trade Tips - Newser
Intraday pattern recognizer results for Insmed IncorporatedQuarterly Portfolio Review & Risk Controlled Daily Plans - Newser
Predicting Insmed Incorporated trend using moving averagesBreakout Watch & Verified Technical Trade Signals - Newser
Will Insmed Incorporated Benefit From Sector Tailwinds getLinesFromResByArray error: size == 0 - 더경남뉴스
Is Insmed Incorporated stock entering bullish territoryEarnings Summary Report & AI Forecast Swing Trade Picks - Newser
Exit strategy if you’re trapped in Insmed IncorporatedTrade Volume Summary & Short-Term High Return Ideas - Newser
Will Insmed Incorporated outperform the marketMarket Trend Review & Precise Buy Zone Tips - Newser
How sentiment analysis helps forecast Insmed IncorporatedQuarterly Earnings Report & Consistent Profit Trading Strategies - Newser
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.21%
3.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):